Research has shown that glycine acts as a signaling molecule in the gut, stimulating specialized L-cells to produce and release GLP-1 and glucagon
GLP1/E therapy led to upregulation of pathways involved in autophagy and vesicle-mediated transport, suggesting that this intervention enhances hypothalamic autophagy, a mechanism that may contribute to the metabolic improvement observed in GLP1/E-treated animals
Potential Benefits and Risks of Microdosing GLP-1 Microdosing GLP-1 is proposed to reduce dose-dependent gastrointestinal side effects such as nausea and vomiting, but lacks randomised controlled trial evidence for efficacy or safety
Around a decade ago, having shifted to a multi-level marketing model, LifeVantage began to ramp up spurious claims about the power of its natural compounds to halt or reverse effects not only of the aging process, but of conditions including cancer and Alzheimers
Common symptoms include nausea, constipation, diarrhea, bloating, and appetite suppression